25 XP   0   0   10

BioLineRx Ltd
Buy, Hold or Sell?

Let's analyse Biolinerx together

PenkeI guess you are interested in BioLineRx Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of BioLineRx Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about BioLineRx Ltd

I send you an email if I find something interesting about BioLineRx Ltd.

Quick analysis of Biolinerx (30 sec.)










What can you expect buying and holding a share of Biolinerx? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$0.18
Expected worth in 1 year
$-0.17
How sure are you?
30.0%

+ What do you gain per year?

Total Gains per Share
$-0.36
Return On Investment
-52.8%

For what price can you sell your share?

Current Price per Share
$0.68
Expected price per share
$0.55 - $1.02
How sure are you?
50%

1. Valuation of Biolinerx (5 min.)




Live pricePrice per Share (EOD)

$0.68

Intrinsic Value Per Share

$-0.76 - $5.36

Total Value Per Share

$-0.58 - $5.54

2. Growth of Biolinerx (5 min.)




Is Biolinerx growing?

Current yearPrevious yearGrowGrow %
How rich?$13.2m$53.6m-$32m-148.0%

How much money is Biolinerx making?

Current yearPrevious yearGrowGrow %
Making money-$15.9m-$8.2m-$7.6m-48.1%
Net Profit Margin-72.3%0.0%--

How much money comes from the company's main activities?

3. Financial Health of Biolinerx (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#643 / 1011

Most Revenue
#483 / 1011

Most Profit
#640 / 1011

Most Efficient
#549 / 1011

What can you expect buying and holding a share of Biolinerx? (5 min.)

Welcome investor! Biolinerx's management wants to use your money to grow the business. In return you get a share of Biolinerx.

What can you expect buying and holding a share of Biolinerx?

First you should know what it really means to hold a share of Biolinerx. And how you can make/lose money.

Speculation

The Price per Share of Biolinerx is $0.6771. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Biolinerx.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Biolinerx, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $0.18. Based on the TTM, the Book Value Change Per Share is $-0.09 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.10 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Biolinerx.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.19-28.3%-0.23-34.1%-0.13-19.2%-0.13-19.1%-0.11-15.6%
Usd Book Value Change Per Share0.000.2%-0.09-13.2%-0.10-14.8%-0.02-2.9%0.000.1%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.000.2%-0.09-13.2%-0.10-14.8%-0.02-2.9%0.000.1%
Usd Price Per Share1.57-1.47-1.13-1.68-1.50-
Price to Earnings Ratio-2.05--1.63--3.10--4.29--5.64-
Price-to-Total Gains Ratio1,277.86-418.27--26.71-53.33-19.88-
Price to Book Ratio8.60-6.44-1.47-3.71-3.03-
Price-to-Total Gains Ratio1,277.86-418.27--26.71-53.33-19.88-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.6771
Number of shares1476
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.09-0.02
Usd Total Gains Per Share-0.09-0.02
Gains per Quarter (1476 shares)-131.89-28.63
Gains per Year (1476 shares)-527.55-114.50
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-528-5380-115-125
20-1055-10660-229-240
30-1583-15940-344-355
40-2110-21220-458-470
50-2638-26500-573-585
60-3165-31780-687-700
70-3693-37060-802-815
80-4220-42340-916-930
90-4748-47620-1031-1045
100-5275-52900-1145-1160

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%1.039.00.02.5%2.055.00.03.5%
Book Value Change Per Share1.02.01.025.0%3.08.01.025.0%5.014.01.025.0%12.027.01.030.0%15.038.04.026.3%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%0.00.057.00.0%
Total Gains per Share1.02.01.025.0%3.08.01.025.0%5.014.01.025.0%12.027.01.030.0%15.038.04.026.3%

Fundamentals of Biolinerx

About BioLineRx Ltd

BioLineRx Ltd., a pre-commercial-stage biopharmaceutical company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; and MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer, as well as licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Modi'in, Israel.

Fundamental data was last updated by Penke on 2024-04-11 02:42:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is less efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is just not able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is overpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of BioLineRx Ltd.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Biolinerx earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Biolinerx to the Biotechnology industry mean.
  • A Net Profit Margin of -289.3% means that $-2.89 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of BioLineRx Ltd:

  • The MRQ is -289.3%. The company is making a huge loss. -2
  • The TTM is -72.3%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-289.3%TTM-72.3%-216.9%
TTM-72.3%YOY--72.3%
TTM-72.3%5Y-14.5%-57.9%
5Y-14.5%10Y-7.2%-7.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-289.3%-196.1%-93.2%
TTM-72.3%-211.9%+139.6%
YOY--277.7%+277.7%
5Y-14.5%-432.9%+418.4%
10Y-7.2%-599.3%+592.1%
1.1.2. Return on Assets

Shows how efficient Biolinerx is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Biolinerx to the Biotechnology industry mean.
  • -21.7% Return on Assets means that Biolinerx generated $-0.22 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of BioLineRx Ltd:

  • The MRQ is -21.7%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -26.5%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-21.7%TTM-26.5%+4.8%
TTM-26.5%YOY-11.6%-14.9%
TTM-26.5%5Y-14.3%-12.2%
5Y-14.3%10Y-11.6%-2.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-21.7%-13.3%-8.4%
TTM-26.5%-12.7%-13.8%
YOY-11.6%-11.8%+0.2%
5Y-14.3%-14.0%-0.3%
10Y-11.6%-15.9%+4.3%
1.1.3. Return on Equity

Shows how efficient Biolinerx is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Biolinerx to the Biotechnology industry mean.
  • -105.0% Return on Equity means Biolinerx generated $-1.05 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of BioLineRx Ltd:

  • The MRQ is -105.0%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -88.7%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-105.0%TTM-88.7%-16.3%
TTM-88.7%YOY-17.6%-71.1%
TTM-88.7%5Y-32.3%-56.3%
5Y-32.3%10Y-21.2%-11.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-105.0%-16.9%-88.1%
TTM-88.7%-16.0%-72.7%
YOY-17.6%-15.1%-2.5%
5Y-32.3%-19.7%-12.6%
10Y-21.2%-20.5%-0.7%

1.2. Operating Efficiency of BioLineRx Ltd.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Biolinerx is operating .

  • Measures how much profit Biolinerx makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Biolinerx to the Biotechnology industry mean.
  • An Operating Margin of -247.1% means the company generated $-2.47  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of BioLineRx Ltd:

  • The MRQ is -247.1%. The company is operating very inefficient. -2
  • The TTM is -61.8%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-247.1%TTM-61.8%-185.4%
TTM-61.8%YOY--61.8%
TTM-61.8%5Y-12.4%-49.4%
5Y-12.4%10Y-6.2%-6.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-247.1%-290.9%+43.8%
TTM-61.8%-224.4%+162.6%
YOY--288.3%+288.3%
5Y-12.4%-479.5%+467.1%
10Y-6.2%-625.2%+619.0%
1.2.2. Operating Ratio

Measures how efficient Biolinerx is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 3.47 means that the operating costs are $3.47 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of BioLineRx Ltd:

  • The MRQ is 3.471. The company is inefficient in keeping operating costs low. -1
  • The TTM is 0.868. The company is less efficient in keeping operating costs low.
Trends
Current periodCompared to+/- 
MRQ3.471TTM0.868+2.604
TTM0.868YOY-+0.868
TTM0.8685Y0.174+0.694
5Y0.17410Y0.087+0.087
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.4713.110+0.361
TTM0.8683.266-2.398
YOY-3.783-3.783
5Y0.1745.657-5.483
10Y0.0877.783-7.696

1.3. Liquidity of BioLineRx Ltd.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Biolinerx is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 1.53 means the company has $1.53 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of BioLineRx Ltd:

  • The MRQ is 1.529. The company is able to pay all its short-term debts. +1
  • The TTM is 2.489. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ1.529TTM2.489-0.959
TTM2.489YOY5.246-2.757
TTM2.4895Y3.942-1.453
5Y3.94210Y7.496-3.554
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.5293.905-2.376
TTM2.4894.212-1.723
YOY5.2465.337-0.091
5Y3.9426.062-2.120
10Y7.4966.401+1.095
1.3.2. Quick Ratio

Measures if Biolinerx is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Biolinerx to the Biotechnology industry mean.
  • A Quick Ratio of 2.67 means the company can pay off $2.67 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of BioLineRx Ltd:

  • The MRQ is 2.672. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 4.157. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ2.672TTM4.157-1.485
TTM4.157YOY9.091-4.934
TTM4.1575Y6.802-2.644
5Y6.80210Y13.546-6.744
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.6723.572-0.900
TTM4.1574.001+0.156
YOY9.0915.364+3.727
5Y6.8026.009+0.793
10Y13.5466.287+7.259

1.4. Solvency of BioLineRx Ltd.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Biolinerx assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Biolinerx to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.79 means that Biolinerx assets are financed with 79.3% credit (debt) and the remaining percentage (100% - 79.3%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of BioLineRx Ltd:

  • The MRQ is 0.793. The company is just able to pay all its debts by selling its assets.
  • The TTM is 0.654. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.793TTM0.654+0.139
TTM0.654YOY0.267+0.387
TTM0.6545Y0.381+0.273
5Y0.38110Y0.250+0.132
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.7930.336+0.457
TTM0.6540.334+0.320
YOY0.2670.271-0.004
5Y0.3810.366+0.015
10Y0.2500.389-0.139
1.4.2. Debt to Equity Ratio

Measures if Biolinerx is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Biolinerx to the Biotechnology industry mean.
  • A Debt to Equity ratio of 383.4% means that company has $3.83 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of BioLineRx Ltd:

  • The MRQ is 3.834. The company is unable to pay all its debts with equity. -1
  • The TTM is 2.353. The company is just not able to pay all its debts with equity.
Trends
Current periodCompared to+/- 
MRQ3.834TTM2.353+1.481
TTM2.353YOY0.401+1.952
TTM2.3535Y0.873+1.480
5Y0.87310Y0.505+0.368
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.8340.382+3.452
TTM2.3530.397+1.956
YOY0.4010.341+0.060
5Y0.8730.432+0.441
10Y0.5050.465+0.040

2. Market Valuation of BioLineRx Ltd

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Biolinerx generates.

  • Above 15 is considered overpriced but always compare Biolinerx to the Biotechnology industry mean.
  • A PE ratio of -2.05 means the investor is paying $-2.05 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of BioLineRx Ltd:

  • The EOD is -0.883. Based on the earnings, the company is expensive. -2
  • The MRQ is -2.048. Based on the earnings, the company is expensive. -2
  • The TTM is -1.632. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.883MRQ-2.048+1.165
MRQ-2.048TTM-1.632-0.416
TTM-1.632YOY-3.105+1.473
TTM-1.6325Y-4.291+2.659
5Y-4.29110Y-5.639+1.349
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.883-2.262+1.379
MRQ-2.048-2.599+0.551
TTM-1.632-2.674+1.042
YOY-3.105-4.133+1.028
5Y-4.291-6.258+1.967
10Y-5.639-6.171+0.532
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of BioLineRx Ltd:

  • The EOD is 2.466. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The MRQ is 5.717. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The TTM is -0.630. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD2.466MRQ5.717-3.252
MRQ5.717TTM-0.630+6.347
TTM-0.630YOY-3.105+2.476
TTM-0.6305Y-4.397+3.767
5Y-4.39710Y-4.978+0.582
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD2.466-2.913+5.379
MRQ5.717-3.275+8.992
TTM-0.630-3.508+2.878
YOY-3.105-5.620+2.515
5Y-4.397-8.306+3.909
10Y-4.978-8.854+3.876
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Biolinerx is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 8.60 means the investor is paying $8.60 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of BioLineRx Ltd:

  • The EOD is 3.709. Based on the equity, the company is fair priced.
  • The MRQ is 8.601. Based on the equity, the company is overpriced. -1
  • The TTM is 6.442. Based on the equity, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD3.709MRQ8.601-4.892
MRQ8.601TTM6.442+2.159
TTM6.442YOY1.473+4.969
TTM6.4425Y3.714+2.728
5Y3.71410Y3.032+0.683
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD3.7091.858+1.851
MRQ8.6012.090+6.511
TTM6.4422.091+4.351
YOY1.4732.866-1.393
5Y3.7143.488+0.226
10Y3.0323.836-0.804
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of BioLineRx Ltd.

3.1. Institutions holding BioLineRx Ltd

Institutions are holding 1.668% of the shares of BioLineRx Ltd.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Morgan Stanley - Brokerage Accounts0.328902382616249935.5589
2023-12-31Susquehanna International Group, LLP0.17950129994-107342-45.2279
2023-12-31Atria Wealth Solutions, Inc.0.15240.002211036600
2023-12-31LPL Financial Corp0.13850.0001100323-13387-11.7729
2023-09-30Citadel Advisors Llc0.0814058954-153815-72.292
2023-12-31Values First Advisors Inc0.0720.04945216838207.9011
2023-12-31Envestnet Asset Management Inc0.0644046647466470
2023-12-31Geneos Wealth Management Inc0.05590.00314050000
2023-12-31Qube Research & Technologies0.05580.00014043540400115428.5714
2023-12-31Geode Capital Management, LLC0.0552039993796724.8767
2023-12-31Rathbone Brothers PLC0.0550.00043982000
2023-12-31Virtu Financial LLC0.04190.003830351712330.6656
2023-12-31JPMorgan Chase & Co0.0317022972229720
2023-09-30National Asset Management Inc0.02940.0011213001000088.4956
2023-12-31Rhumbline Advisers0.026018798345822.5424
2023-12-31NorthRock Partners LLC0.02360.002517125171250
2023-12-31Cutter & CO Brokerage, Inc.0.0230.00731666700
2023-12-31Allen, Mooney & Barnes Investment Advisors, LLC0.02070.004515000-10000-40
2023-12-31Creative Planning Inc0.020101458200
2023-12-31Advisor Group Holdings, Inc.0.0198014325-9870-40.7936
Total 1.47520.07451068581-72403-6.8%

3.2. Funds holding BioLineRx Ltd

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-01-31Fidelity Nasdaq Composite Index0.05520.00033999300
2024-02-29ActivePassive International Equity ETF0.00050.000236100
Total 0.05570.00054035400.0%

4. Summary

4.1. Key Performance Indicators

The key performance indicators of BioLineRx Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.001-0.089+7373%-0.100+8238%-0.019+1679%0.001+131%
Book Value Per Share--0.1830.299-39%0.741-75%0.582-69%0.591-69%
Current Ratio--1.5292.489-39%5.246-71%3.942-61%7.496-80%
Debt To Asset Ratio--0.7930.654+21%0.267+197%0.381+108%0.250+218%
Debt To Equity Ratio--3.8342.353+63%0.401+856%0.873+339%0.505+660%
Dividend Per Share----0%-0%-0%-0%
Eps---0.192-0.231+21%-0.130-32%-0.129-33%-0.105-45%
Free Cash Flow Per Share--0.069-0.079+215%-0.099+245%-0.084+222%-0.078+214%
Free Cash Flow To Equity Per Share--0.231-0.027+112%-0.027+112%0.007+3385%0.006+3635%
Gross Profit Margin--1.2171.319-8%1.194+2%1.129+8%1.115+9%
Intrinsic Value_10Y_max--5.361--------
Intrinsic Value_10Y_min---0.763--------
Intrinsic Value_1Y_max---0.190--------
Intrinsic Value_1Y_min---0.303--------
Intrinsic Value_3Y_max---0.017--------
Intrinsic Value_3Y_min---0.719--------
Intrinsic Value_5Y_max--0.825--------
Intrinsic Value_5Y_min---0.923--------
Market Cap49048647.322-132%113729694.720106331831.616+7%81584757.120+39%121884548.467-7%108467523.160+5%
Net Profit Margin---2.893-0.723-75%--100%-0.145-95%-0.072-98%
Operating Margin---2.471-0.618-75%--100%-0.124-95%-0.062-98%
Operating Ratio--3.4710.868+300%-+100%0.174+1900%0.087+3900%
Pb Ratio3.709-132%8.6016.442+34%1.473+484%3.714+132%3.032+184%
Pe Ratio-0.883+57%-2.048-1.632-20%-3.105+52%-4.291+110%-5.639+175%
Price Per Share0.677-132%1.5701.468+7%1.126+39%1.683-7%1.497+5%
Price To Free Cash Flow Ratio2.466-132%5.717-0.630+111%-3.105+154%-4.397+177%-4.978+187%
Price To Total Gains Ratio551.108-132%1277.862418.273+206%-26.709+102%53.327+2296%19.879+6328%
Quick Ratio--2.6724.157-36%9.091-71%6.802-61%13.546-80%
Return On Assets---0.217-0.265+22%-0.116-47%-0.143-34%-0.116-47%
Return On Equity---1.050-0.887-16%-0.176-83%-0.323-69%-0.212-80%
Total Gains Per Share--0.001-0.089+7373%-0.100+8238%-0.019+1679%0.001+131%
Usd Book Value--13223000.00021631250.000-39%53654750.000-75%42174800.000-69%42807364.522-69%
Usd Book Value Change Per Share--0.001-0.089+7373%-0.100+8238%-0.019+1679%0.001+131%
Usd Book Value Per Share--0.1830.299-39%0.741-75%0.582-69%0.591-69%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.192-0.231+21%-0.130-32%-0.129-33%-0.105-45%
Usd Free Cash Flow--4973000.000-5726250.000+215%-7197500.000+245%-6065500.000+222%-5665404.970+214%
Usd Free Cash Flow Per Share--0.069-0.079+215%-0.099+245%-0.084+222%-0.078+214%
Usd Free Cash Flow To Equity Per Share--0.231-0.027+112%-0.027+112%0.007+3385%0.006+3635%
Usd Market Cap49048647.322-132%113729694.720106331831.616+7%81584757.120+39%121884548.467-7%108467523.160+5%
Usd Price Per Share0.677-132%1.5701.468+7%1.126+39%1.683-7%1.497+5%
Usd Profit---13884000.000-15980000.000+15%-8287250.000-40%-8864800.000-36%-6635358.240-52%
Usd Revenue--4800000.0001200000.000+300%-+100%240000.000+1900%120000.000+3900%
Usd Total Gains Per Share--0.001-0.089+7373%-0.100+8238%-0.019+1679%0.001+131%
 EOD+3 -5MRQTTM+19 -15YOY+15 -195Y+13 -2110Y+15 -19

4.2. Fundamental Score

Let's check the fundamental score of BioLineRx Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.883
Price to Book Ratio (EOD)Between0-13.709
Net Profit Margin (MRQ)Greater than0-2.893
Operating Margin (MRQ)Greater than0-2.471
Quick Ratio (MRQ)Greater than12.672
Current Ratio (MRQ)Greater than11.529
Debt to Asset Ratio (MRQ)Less than10.793
Debt to Equity Ratio (MRQ)Less than13.834
Return on Equity (MRQ)Greater than0.15-1.050
Return on Assets (MRQ)Greater than0.05-0.217
Total3/10 (30.0%)

4.3. Technical Score

Let's check the technical score of BioLineRx Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5033.045
Ma 20Greater thanMa 500.810
Ma 50Greater thanMa 1001.050
Ma 100Greater thanMa 2001.251
OpenGreater thanClose0.633
Total0/5 (0.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Net Interest Income  -542152-390-507-897372-5252,1751,650



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets63,925
Total Liabilities50,702
Total Stockholder Equity13,223
 As reported
Total Liabilities 50,702
Total Stockholder Equity+ 13,223
Total Assets = 63,925

Assets

Total Assets63,925
Total Current Assets47,183
Long-term Assets16,742
Total Current Assets
Cash And Cash Equivalents 4,255
Short-term Investments 38,739
Net Receivables 708
Inventory 1,953
Other Current Assets 1,528
Total Current Assets  (as reported)47,183
Total Current Assets  (calculated)47,183
+/-0
Long-term Assets
Property Plant Equipment 1,888
Intangible Assets 14,854
Long-term Assets Other 0
Long-term Assets  (as reported)16,742
Long-term Assets  (calculated)16,742
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities30,852
Long-term Liabilities19,850
Total Stockholder Equity13,223
Total Current Liabilities
Short-term Debt 3,673
Short Long Term Debt 3,145
Accounts payable 10,869
Other Current Liabilities 3,353
Total Current Liabilities  (as reported)30,852
Total Current Liabilities  (calculated)21,040
+/- 9,812
Long-term Liabilities
Long term Debt 6,628
Capital Lease Obligations 1,818
Long-term Liabilities  (as reported)19,850
Long-term Liabilities  (calculated)8,446
+/- 11,404
Total Stockholder Equity
Common Stock31,355
Retained Earnings -390,606
Accumulated Other Comprehensive Income 16,992
Other Stockholders Equity 355,482
Total Stockholder Equity (as reported)13,223
Total Stockholder Equity (calculated)13,223
+/-0
Other
Capital Stock31,355
Cash and Short Term Investments 42,994
Common Stock Shares Outstanding 72,439
Current Deferred Revenue12,957
Liabilities and Stockholders Equity 63,925
Net Debt 7,336
Net Invested Capital 22,996
Net Working Capital 16,331
Property Plant and Equipment Gross 7,428
Short Long Term Debt Total 11,591



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-31
> Total Assets 
159,167
0
0
0
43,570
41,022
37,713
33,043
29,338
39,313
33,343
28,165
24,307
30,658
24,956
22,142
19,948
38,977
35,034
30,958
36,166
59,873
58,355
55,031
51,302
48,941
45,680
42,277
38,939
41,118
63,048
66,127
60,965
56,075
52,213
46,400
56,233
67,594
61,958
57,225
53,567
47,171
52,989
46,039
47,290
83,599
91,329
86,905
81,391
74,773
67,838
81,673
68,646
68,646
58,936
52,855
63,925
63,92552,85558,93668,64668,64681,67367,83874,77381,39186,90591,32983,59947,29046,03952,98947,17153,56757,22561,95867,59456,23346,40052,21356,07560,96566,12763,04841,11838,93942,27745,68048,94151,30255,03158,35559,87336,16630,95835,03438,97719,94822,14224,95630,65824,30728,16533,34339,31329,33833,04337,71341,02243,570000159,167
   > Total Current Assets 
147,047
0
0
0
0
38,383
35,087
30,680
27,156
37,148
31,368
26,266
22,178
28,976
23,334
20,553
18,773
37,826
33,894
29,897
35,114
58,430
55,692
51,885
48,183
45,869
42,694
39,414
36,101
31,648
53,663
55,847
50,376
45,544
42,797
37,104
31,978
41,649
36,207
31,702
28,210
22,140
28,169
21,423
22,880
59,352
67,072
62,846
57,404
50,941
44,103
57,942
44,327
44,327
34,692
28,805
47,183
47,18328,80534,69244,32744,32757,94244,10350,94157,40462,84667,07259,35222,88021,42328,16922,14028,21031,70236,20741,64931,97837,10442,79745,54450,37655,84753,66331,64836,10139,41442,69445,86948,18351,88555,69258,43035,11429,89733,89437,82618,77320,55323,33428,97622,17826,26631,36837,14827,15630,68035,08738,3830000147,047
       Cash And Cash Equivalents 
105,890
0
0
0
31,490
15,630
11,062
9,051
8,687
25,236
16,309
13,429
18,292
12,765
13,770
12,041
8,869
9,123
8,437
4,715
5,783
8,075
9,404
5,320
5,544
4,584
3,877
4,014
2,469
2,201
6,946
6,712
5,110
7,810
5,789
4,703
3,404
4,384
4,972
4,885
5,297
5,072
5,523
6,552
16,831
16,047
17,484
14,077
12,990
11,446
14,000
13,105
9,066
9,066
10,104
7,727
4,255
4,2557,72710,1049,0669,06613,10514,00011,44612,99014,07717,48416,04716,8316,5525,5235,0725,2974,8854,9724,3843,4044,7035,7897,8105,1106,7126,9462,2012,4694,0143,8774,5845,5445,3209,4048,0755,7834,7158,4379,1238,86912,04113,77012,76518,29213,42916,30925,2368,6879,05111,06215,63031,490000105,890
       Short-term Investments 
0
0
0
0
7,901
20,915
0
20,980
17,284
11,097
14,332
12,337
3,067
15,274
9,111
8,040
9,288
28,212
24,760
24,945
28,854
49,418
45,385
45,387
42,119
40,423
37,945
34,894
33,154
28,167
45,616
48,295
44,373
36,388
35,339
30,300
26,747
36,224
30,256
25,255
22,192
16,109
21,779
14,275
5,756
42,036
48,083
48,128
44,145
39,144
29,146
44,157
34,221
34,221
22,711
18,241
38,739
38,73918,24122,71134,22134,22144,15729,14639,14444,14548,12848,08342,0365,75614,27521,77916,10922,19225,25530,25636,22426,74730,30035,33936,38844,37348,29545,61628,16733,15434,89437,94540,42342,11945,38745,38549,41828,85424,94524,76028,2129,2888,0409,11115,2743,06712,33714,33211,09717,28420,980020,9157,9010000
       Net Receivables 
40,063
0
0
0
0
1,806
1,910
564
1,005
499
451
461
603
706
299
245
359
226
414
60
257
641
653
992
291
396
548
303
223
580
541
558
586
782
438
835
1,339
458
528
1,285
613
682
441
327
141
190
668
192
142
190
240
143
302
302
128
315
708
7083151283023021432401901421926681901413274416826131,2855284581,339835438782586558541580223303548396291992653641257604142263592452997066034614514991,0055641,9101,806000040,063
       Other Current Assets 
1,094
0
0
0
13
0
22,058
85
11,148
11,148
276
12,248
215
232
9,111
227
28,212
28,212
24,760
176
49,418
49,418
45,385
45,387
40,423
40,423
37,945
34,894
28,167
28,167
45,616
48,295
44,373
564
1,231
1,266
488
0
451
277
108
0
426
269
152
0
837
449
127
0
717
537
738
0
1,749
1,170
1,528
1,5281,1701,749073853771701274498370152269426010827745104881,2661,23156444,37348,29545,61628,16728,16734,89437,94540,42340,42345,38745,38549,41849,41817624,76028,21228,2122279,11123221512,24827611,14811,1488522,0580130001,094
   > Long-term Assets 
0
0
0
0
0
2,639
2,626
2,363
2,182
2,165
1,974
1,898
2,129
1,682
1,623
1,589
1,175
1,151
1,141
1,061
1,052
1,443
2,663
3,146
3,119
3,072
2,986
2,863
2,838
9,470
9,385
10,280
10,589
10,531
9,416
9,296
24,255
25,945
25,751
25,523
25,357
25,031
24,820
24,616
24,410
24,247
24,257
24,059
23,987
23,832
23,735
23,731
24,319
24,319
24,244
24,050
16,742
16,74224,05024,24424,31924,31923,73123,73523,83223,98724,05924,25724,24724,41024,61624,82025,03125,35725,52325,75125,94524,2559,2969,41610,53110,58910,2809,3859,4702,8382,8632,9863,0723,1193,1462,6631,4431,0521,0611,1411,1511,1751,5891,6231,6822,1291,8981,9742,1652,1822,3632,6262,63900000
       Property Plant Equipment 
4,175
0
0
0
1,271
1,242
1,237
1,088
1,106
1,069
932
868
849
807
787
751
710
687
680
632
720
1,111
2,489
2,962
2,909
2,859
2,770
2,654
2,605
2,540
2,463
2,365
2,505
2,432
2,318
2,197
2,227
3,940
3,763
3,558
3,466
3,263
3,070
2,885
2,696
2,540
2,551
2,354
2,283
2,128
2,031
2,015
2,358
2,358
2,231
2,023
1,888
1,8882,0232,2312,3582,3582,0152,0312,1282,2832,3542,5512,5402,6962,8853,0703,2633,4663,5583,7633,9402,2272,1972,3182,4322,5052,3652,4632,5402,6052,6542,7702,8592,9092,9622,4891,1117206326806877107517878078498689321,0691,1061,0881,2371,2421,2710004,175
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
21,682
21,694
21,939
0
21,991
0
0
0021,991021,93921,69421,68200000000000000000000000000000000000000000000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,000
1,000
1,000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000001,0001,0001,0000000000000000000000000000000000
       Intangible Assets 
3,042
0
0
0
381
372
350
315
301
303
279
269
285
289
255
255
252
245
248
227
117
116
117
128
152
157
162
155
181
6,875
6,869
6,855
7,023
7,039
7,035
7,033
21,972
21,950
21,928
21,906
21,891
21,768
0
0
21,714
0
0
0
21,704
0
22
22
22
0
22
0
14,854
14,8540220222222021,70400021,7140021,76821,89121,90621,92821,95021,9727,0337,0357,0397,0236,8556,8696,8751811551621571521281171161172272482452522552552892852692793033013153503723810003,042
       Long-term Assets Other 
0
0
0
0
0
1,025
1,039
960
775
793
764
761
995
586
580
582
213
219
213
202
214
216
57
56
58
56
54
54
52
55
53
60
61
60
63
66
56
55
60
59
25,357
25,031
21,750
21,731
21,398
0
21,706
21,705
0
21,704
0
0
0
0
0
0
0
000000021,704021,70521,706021,39821,73121,75025,03125,3575960555666636061605355525454565856572162142022132192135825805869957617647937759601,0391,02500000
> Total Liabilities 
41,230
0
0
0
6,384
6,485
6,941
6,681
6,806
11,194
9,367
9,901
9,336
10,399
7,663
8,063
8,265
6,747
5,749
4,093
4,400
5,685
6,539
4,360
3,692
2,939
3,116
3,668
3,912
5,402
5,618
7,102
8,084
7,053
6,027
5,815
14,912
21,706
20,176
18,027
20,187
18,663
23,759
21,231
25,260
18,952
17,436
16,004
13,304
11,360
11,270
26,149
29,532
29,532
37,882
39,721
50,702
50,70239,72137,88229,53229,53226,14911,27011,36013,30416,00417,43618,95225,26021,23123,75918,66320,18718,02720,17621,70614,9125,8156,0277,0538,0847,1025,6185,4023,9123,6683,1162,9393,6924,3606,5395,6854,4004,0935,7496,7478,2658,0637,66310,3999,3369,9019,36711,1946,8066,6816,9416,4856,38400041,230
   > Total Current Liabilities 
41,230
0
0
0
6,254
6,376
6,852
6,622
6,755
7,404
6,470
6,716
6,427
7,452
5,196
4,333
2,999
3,190
2,754
2,615
2,902
4,145
4,152
3,590
3,140
2,559
2,805
3,367
3,661
5,174
5,414
5,526
6,722
6,180
5,338
4,925
6,751
8,135
8,559
10,091
11,968
11,766
11,723
10,476
10,641
10,216
9,917
10,313
9,719
9,098
9,632
8,133
12,041
12,041
12,446
14,725
30,852
30,85214,72512,44612,04112,0418,1339,6329,0989,71910,3139,91710,21610,64110,47611,72311,76611,96810,0918,5598,1356,7514,9255,3386,1806,7225,5265,4145,1743,6613,3672,8052,5593,1403,5904,1524,1452,9022,6152,7543,1902,9994,3335,1967,4526,4276,7166,4707,4046,7556,6226,8526,3766,25400041,230
       Short-term Debt 
0
0
0
0
0
88
90
82
81
83
65
44
37
15
0
0
0
0
0
0
0
0
0
93
93
93
93
93
93
93
93
93
93
93
93
93
895
2,329
3,067
3,815
2,894
2,974
3,067
3,169
3,283
3,360
3,528
3,744
2,925
2,050
1,162
953
2,937
2,937
3,453
3,604
3,673
3,6733,6043,4532,9372,9379531,1622,0502,9253,7443,5283,3603,2833,1693,0672,9742,8943,8153,0672,3298959393939393939393939393939300000000015374465838182908800000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
93
0
0
0
93
320
296
93
93
93
93
93
895
1,636
2,395
3,164
2,692
2,777
2,867
2,969
3,092
3,220
3,354
3,575
2,757
1,903
1,013
802
1,542
2,558
3,078
3,078
3,145
3,1453,0783,0782,5581,5428021,0131,9032,7573,5753,3543,2203,0922,9692,8672,7772,6923,1642,3951,63689593939393932963209300093000000000000000000000000
       Accounts payable 
6,452
0
0
0
1,751
886
1,259
1,482
2,962
3,281
2,805
2,967
3,288
5,987
4,135
3,521
2,281
1,970
1,864
1,521
1,652
2,614
2,959
2,349
1,910
1,465
1,732
2,274
2,590
3,450
4,262
4,349
5,516
4,941
4,128
3,804
4,493
4,817
4,565
5,303
7,794
7,489
7,396
5,933
5,918
5,756
5,318
5,441
5,567
5,784
7,338
5,829
7,136
7,136
6,733
8,438
10,869
10,8698,4386,7337,1367,1365,8297,3385,7845,5675,4415,3185,7565,9185,9337,3967,4897,7945,3034,5654,8174,4933,8044,1284,9415,5164,3494,2623,4502,5902,2741,7321,4651,9102,3492,9592,6141,6521,5211,8641,9702,2813,5214,1355,9873,2882,9672,8053,2812,9621,4821,2598861,7510006,452
       Other Current Liabilities 
34,778
0
0
0
4,416
5,402
5,504
5,058
3,712
4,041
3,600
3,705
2,419
1,451
1,061
812
718
1,220
891
1,094
1,250
1,531
1,193
1,148
1,137
1,001
980
1,000
978
1,631
1,059
1,084
1,113
1,146
1,117
1,028
1,363
693
927
973
1,280
1,303
1,260
1,374
1,440
1,100
1,071
1,128
1,227
1,264
1,132
1,351
1,968
1,968
2,260
2,683
3,353
3,3532,6832,2601,9681,9681,3511,1321,2641,2271,1281,0711,1001,4401,3741,2601,3031,2809739276931,3631,0281,1171,1461,1131,0841,0591,6319781,0009801,0011,1371,1481,1931,5311,2501,0948911,2207188121,0611,4512,4193,7053,6004,0413,7125,0585,5045,4024,41600034,778
   > Long-term Liabilities 
0
0
0
0
0
109
88
59
51
3,790
2,897
3,185
2,909
2,947
2,467
3,730
5,266
3,557
2,995
1,478
1,498
1,540
2,387
770
552
380
311
301
251
228
204
1,576
1,362
873
689
890
8,161
13,571
11,617
7,936
8,219
6,897
12,036
10,755
14,619
8,736
7,519
5,691
3,585
2,262
1,638
18,016
17,491
17,491
25,436
24,996
19,850
19,85024,99625,43617,49117,49118,0161,6382,2623,5855,6917,5198,73614,61910,75512,0366,8978,2197,93611,61713,5718,1618906898731,3621,5762042282513013113805527702,3871,5401,4981,4782,9953,5575,2663,7302,4672,9472,9093,1852,8973,79051598810900000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
7,838
8,358
7,679
7,073
7,561
6,715
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000006,7157,5617,0737,6798,3587,838000000000000000000000000000000000000
       Other Liabilities 
0
0
0
0
8
0
0
0
22
3,765
2,880
3,208
2,917
2,958
2,480
3,746
5,270
3,567
3,006
1,480
1,494
1,540
2,387
404
208
60
15
29
1
1
1
1,396
1,205
740
580
804
323
5,213
3,938
863
658
182
6,077
5,600
10,218
5,247
4,812
4,013
1,859
604
186
8,156
0
0
15,352
0
0
0015,352008,1561866041,8594,0134,8125,24710,2185,6006,0771826588633,9385,2133238045807401,2051,3961112915602084042,3871,5401,4941,4803,0063,5675,2703,7462,4802,9582,9173,2082,8803,7652200080000
> Total Stockholder Equity
117,937
0
0
0
37,186
34,537
30,772
26,362
22,532
28,119
23,975
18,264
14,971
20,258
17,293
14,079
11,683
32,230
29,285
26,865
31,766
54,188
51,816
50,671
47,610
46,002
42,564
38,609
35,027
35,716
57,430
59,025
52,881
49,022
46,186
40,585
41,321
45,888
41,782
39,198
33,380
28,508
29,230
24,808
22,030
64,647
73,893
70,901
68,087
63,413
56,568
55,524
39,114
39,114
21,054
13,134
13,223
13,22313,13421,05439,11439,11455,52456,56863,41368,08770,90173,89364,64722,03024,80829,23028,50833,38039,19841,78245,88841,32140,58546,18649,02252,88159,02557,43035,71635,02738,60942,56446,00247,61050,67151,81654,18831,76626,86529,28532,23011,68314,07917,29320,25814,97118,26423,97528,11922,53226,36230,77234,53737,186000117,937
   Common Stock
1,235
0
0
0
348
353
361
330
325
474
450
447
492
609
629
661
693
970
994
926
1,004
1,420
1,448
1,450
1,455
1,459
1,459
1,460
1,513
1,642
2,570
2,809
2,836
2,874
2,920
2,922
3,110
3,928
4,001
4,129
4,692
4,907
8,281
8,281
9,870
18,731
20,496
20,874
21,066
21,066
21,157
27,098
27,100
27,100
27,100
28,332
31,355
31,35528,33227,10027,10027,10027,09821,15721,06621,06620,87420,49618,7319,8708,2818,2814,9074,6924,1294,0013,9283,1102,9222,9202,8742,8362,8092,5701,6421,5131,4601,4591,4591,4551,4501,4481,4201,0049269949706936616296094924474504743253303613533480001,235
   Retained Earnings -390,606-376,722-360,699-342,154-342,154-324,261-317,414-309,971-305,041-300,737-295,021-288,179-277,987-265,999-261,381-254,611-247,966-238,098-234,160-228,675-222,520-216,868-210,544-205,756-199,558-192,201-184,958-180,061-175,206-170,921-166,588-162,854-159,365-155,713-154,086-149,276-140,063-143,752-153,607-146,548-145,234-137,448-129,589-125,130-118,936-106,603-101,534-103,908-96,708-94,497-101,033-94,0970000-325,323
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
250,192
259,860
261,522
262,430
265,938
267,140
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000267,140265,938262,430261,522259,860250,192000000000000000000000000000000000000
   Treasury Stock000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
442,025
0
0
0
0
128,281
131,444
120,529
118,915
122,874
125,059
116,040
124,367
135,413
136,761
141,343
146,405
167,758
171,471
160,079
161,459
193,426
195,583
195,950
196,201
197,792
197,858
198,380
199,567
205,892
231,368
239,606
240,682
242,177
243,883
244,058
250,192
259,860
261,522
262,430
265,938
267,140
271,107
271,107
279,241
322,895
336,862
339,026
340,321
340,419
340,645
340,249
340,450
340,450
340,453
346,870
355,482
355,482346,870340,453340,450340,450340,249340,645340,419340,321339,026336,862322,895279,241271,107271,107267,140265,938262,430261,522259,860250,192244,058243,883242,177240,682239,606231,368205,892199,567198,380197,858197,792196,201195,950195,583193,426161,459160,079171,471167,758146,405141,343136,761135,413124,367116,040125,059122,874118,915120,529131,444128,2810000442,025



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue4,800
Cost of Revenue-4,626
Gross Profit174174
 
Operating Income (+$)
Gross Profit174
Operating Expense-43,165
Operating Income-42,991-42,991
 
Operating Expense (+$)
Research Development11,936
Selling General Administrative16,637
Selling And Marketing Expenses14,593
Operating Expense43,16543,166
 
Net Interest Income (+$)
Interest Income2,007
Interest Expense-2,144
Other Finance Cost-25
Net Interest Income-162
 
Pretax Income (+$)
Operating Income-42,991
Net Interest Income-162
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-60,614-25,368
EBIT - interestExpense = -45,135
-60,614
-58,470
Interest Expense2,144
Earnings Before Interest and Taxes (EBIT)-42,991-58,470
Earnings Before Interest and Taxes (EBITDA)-41,607
 
After tax Income (+$)
Income Before Tax-60,614
Tax Provision-0
Net Income From Continuing Ops-60,615-60,614
Net Income-60,614
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses47,791
Total Other Income/Expenses Net-17,623162
 

Technical Analysis of Biolinerx
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Biolinerx. The general trend of Biolinerx is BEARISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Biolinerx's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-100.0%) Bearish trend (100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of BioLineRx Ltd.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 0.9943 < 1.01 < 1.02.

The bearish price targets are: 0.62 > 0.62 > 0.55.

Tweet this
BioLineRx Ltd Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of BioLineRx Ltd. The current mas is .

The long score for the Moving Averages is 0/14.
The longshort score for the Moving Averages is -14/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

BioLineRx Ltd Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of BioLineRx Ltd. The current macd is -0.13190673.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Biolinerx price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Biolinerx. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Biolinerx price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
BioLineRx Ltd Daily Moving Average Convergence/Divergence (MACD) ChartBioLineRx Ltd Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of BioLineRx Ltd. The current adx is 38.91.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -4/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Biolinerx shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bearish trend. The ADX is trending up, so the bearish trend is strengthening.
BioLineRx Ltd Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of BioLineRx Ltd. The current sar is 0.71906122.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
BioLineRx Ltd Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of BioLineRx Ltd. The current rsi is 33.04. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending up: The RSI is trending up. +1
BioLineRx Ltd Daily Relative Strength Index (RSI) ChartBioLineRx Ltd Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of BioLineRx Ltd. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Biolinerx price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
BioLineRx Ltd Daily Stochastic Oscillator ChartBioLineRx Ltd Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of BioLineRx Ltd. The current cci is -68.44891414.

BioLineRx Ltd Daily Commodity Channel Index (CCI) ChartBioLineRx Ltd Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of BioLineRx Ltd. The current cmo is -32.11661697.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
BioLineRx Ltd Daily Chande Momentum Oscillator (CMO) ChartBioLineRx Ltd Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of BioLineRx Ltd. The current willr is -72.93263413.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Biolinerx is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
BioLineRx Ltd Daily Williams %R ChartBioLineRx Ltd Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of BioLineRx Ltd.

BioLineRx Ltd Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of BioLineRx Ltd. The current atr is 0.07944747.

BioLineRx Ltd Daily Average True Range (ATR) ChartBioLineRx Ltd Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of BioLineRx Ltd. The current obv is -29,157,667.

BioLineRx Ltd Daily On-Balance Volume (OBV) ChartBioLineRx Ltd Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of BioLineRx Ltd. The current mfi is 14.98.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -2/(-2 +2).

  • MFI < 50: -1
  • MFI < 20: -1
BioLineRx Ltd Daily Money Flow Index (MFI) ChartBioLineRx Ltd Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for BioLineRx Ltd.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-30STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-01CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-04MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2023-12-07SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-11STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-13STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-14STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-15CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-18MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-20STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-21CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-22CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-26DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-12-28DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-29DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-02STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-05MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-08DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-01-10DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-11CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-12BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-17STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-19STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-23STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-24BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-26STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-29RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-30SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-01-31STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-01CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-05SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-06MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-08MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-02-09RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-13MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-14STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-16SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-21STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-22STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-23STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-26DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-27STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-28STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-03-01STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-07CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-08DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-11MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-03-13STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-21DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-22MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-26MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-28STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-01STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-03STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-09STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-04-10RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-04-12RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-04-15STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-19RSI LONG ENTRY SHORT CLOSE30 crossover to upside

6.3. Candlestick Patterns

BioLineRx Ltd Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of BioLineRx Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5033.045
Ma 20Greater thanMa 500.810
Ma 50Greater thanMa 1001.050
Ma 100Greater thanMa 2001.251
OpenGreater thanClose0.633
Total0/5 (0.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Biolinerx with someone you think should read this too:
  • Are you bullish or bearish on Biolinerx? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Biolinerx? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about BioLineRx Ltd

I send you an email if I find something interesting about BioLineRx Ltd.


Comments

How you think about this?

Leave a comment

Stay informed about BioLineRx Ltd.

Receive notifications about BioLineRx Ltd in your mailbox!